Page last updated: 2024-08-21

ethambutol and SAPHO Syndrome

ethambutol has been researched along with SAPHO Syndrome in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Furuta, S; Furuya, H; Hirose, K; Ikeda, K; Miyachi, K; Nakajima, H; Nakamura, K; Sakagami, T; Suzuki, K; Tamachi, T	1
Dannecker, G; Hess, S; Hospach, T; Magdorf, K; Nossal, R; Uhlemann, F	1

Other Studies

2 other study(ies) available for ethambutol and SAPHO Syndrome

Article	Year
SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. Rheumatology (Oxford, England), 2017, Jul-01, Volume: 56, Issue:7 Topics: Acquired Hyperostosis Syndrome; Anti-Bacterial Agents; Autoantibodies; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Humans; Interferon-gamma; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Rifampin; Treatment Outcome	2017
Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. European journal of pediatrics, 2011, Volume: 170, Issue:10 Topics: Acquired Hyperostosis Syndrome; Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Dyspnea; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Immunosuppressive Agents; Moxifloxacin; Quinolines; Severity of Illness Index; Shock, Septic; Treatment Outcome; Tuberculosis, Miliary; Tumor Necrosis Factor-alpha	2011

Article

Year

SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody.

Rheumatology (Oxford, England), 2017, Jul-01, Volume: 56, Issue:7

Topics: Acquired Hyperostosis Syndrome; Anti-Bacterial Agents; Autoantibodies; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Humans; Interferon-gamma; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Rifampin; Treatment Outcome

2017

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

European journal of pediatrics, 2011, Volume: 170, Issue:10

Topics: Acquired Hyperostosis Syndrome; Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Dyspnea; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Immunosuppressive Agents; Moxifloxacin; Quinolines; Severity of Illness Index; Shock, Septic; Treatment Outcome; Tuberculosis, Miliary; Tumor Necrosis Factor-alpha

2011